AZ will withdraw its KRW 50 bil Forxiga from KOR mkt
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.12.11 13:29:03
가나다라
0
Due to intensified competition after the drug’s patent expiry...AZ "made the decision to discontinue domestic supply"
KRW 50 billion void in the single-agent market will be inevitable...foreshadows increased generic competition
Forxiga (dapagliflozin), an SGLT-2 inhibitor class diabetes drug worth KRW 50 billion a year, will withdraw from the domestic market.
According to industry sources on the 11th, AstraZeneca Korea recently made the decision to discontinue supply of Forxiga in Korea. However, the company will continue to supply its dapagliflozin and metformin combination drug Xigduo in Korea.
An official from AstraZeneca told Dailypharm, "We have decided to discontinue the domestic supply of Forxiga in Korea to reorganize our portfolio. We have started discussions with the Ministry of Food and Drug Safety regarding withdrawing our marketing authorization. We will do our best to ensure that there is
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)